XFRA CAPITAL ADJUSTMENT INFORMATION

Realtime	Geld	Brief	Zeit
	0,363	0,378	23.12.
	0,361	0,381	23.12.

Realtime

Geld

Brief

Zeit

0,363

0,378

23.12.

0,361

0,381

23.12.

XFRA CAPITAL ADJUSTMENT INFORMATION - 12.08.2024

Das Instrument 1YR SE0006091997 IMMUNOVIA AB EQUITY wird cum Kapitalmassnahme gehandelt am 12.08.2024 und ex Kapitalmassnahme am 13.08.2024
The instrument 1YR SE0006091997 IMMUNOVIA AB EQUITY is traded cum capital adjustment on 12.08.2024 and ex capital adjustment on 13.08.2024

Das Instrument 6T40 US89532E2081 TREVENA INC. DL-,001 EQUITY wird cum Kapitalmassnahme gehandelt am 12.08.2024 und ex Kapitalmassnahme am 13.08.2024
The instrument 6T40 US89532E2081 TREVENA INC. DL-,001 EQUITY is traded cum capital adjustment on 12.08.2024 and ex capital adjustment on 13.08.2024

Das Instrument ET80 CA0079756007 AETERNA ZENTARIS INC. EQUITY wird cum Kapitalmassnahme gehandelt am 12.08.2024 und ex Kapitalmassnahme am 13.08.2024
The instrument ET80 CA0079756007 AETERNA ZENTARIS INC. EQUITY is traded cum capital adjustment on 12.08.2024 and ex capital adjustment on 13.08.2024

Das Instrument 4SM NO0010187032 MAGNORA ASA NK 0,50 EQUITY wird cum Kapitalmassnahme gehandelt am 12.08.2024 und ex Kapitalmassnahme am 13.08.2024
The instrument 4SM NO0010187032 MAGNORA ASA NK 0,50 EQUITY is traded cum capital adjustment on 12.08.2024 and ex capital adjustment on 13.08.2024

Das Instrument EM3A BMG3036C2239 EMPEROR INTL SUBDIV.HD-01 EQUITY wird cum Kapitalmassnahme gehandelt am 12.08.2024 und ex Kapitalmassnahme am 13.08.2024
The instrument EM3A BMG3036C2239 EMPEROR INTL SUBDIV.HD-01 EQUITY is traded cum capital adjustment on 12.08.2024 and ex capital adjustment on 13.08.2024

Das Instrument 13X KYG9829N1025 XINYI SOLAR HLDGS EQUITY wird cum Kapitalmassnahme gehandelt am 12.08.2024 und ex Kapitalmassnahme am 13.08.2024
The instrument 13X KYG9829N1025 XINYI SOLAR HLDGS EQUITY is traded cum capital adjustment on 12.08.2024 and ex capital adjustment on 13.08.2024

Das Instrument PDA DE0006967805 PRO DV AG O.N. EQUITY wird cum Kapitalmassnahme gehandelt am 12.08.2024 und ex Kapitalmassnahme am 13.08.2024
The instrument PDA DE0006967805 PRO DV AG O.N. EQUITY is traded cum capital adjustment on 12.08.2024 and ex capital adjustment on 13.08.2024

Treibt Nvidias KI-Boom den Uranpreis?

In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.

Hier klicken

Zeit	Aktuelle Nachrichten
Mo	Cosciens Biopharma Inc: Cosciens talks cost-cutting in 2024, focus for 2025
Mo	COSCIENS Biopharma halts investment in macimorelin; CMO to depart
Mo	COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization	Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations... ► Artikel lesen
Mo	COSCIENS Biopharma Inc. - 6-K, Report of foreign issuer
12.11.	COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs	Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12, 2024 (GLOBE... ► Artikel lesen

Zeit

Aktuelle Nachrichten

Cosciens Biopharma Inc: Cosciens talks cost-cutting in 2024, focus for 2025

COSCIENS Biopharma halts investment in macimorelin; CMO to depart

COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization

Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations...
► Artikel lesen

COSCIENS Biopharma Inc. - 6-K, Report of foreign issuer

12.11.

COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs

Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12, 2024 (GLOBE...
► Artikel lesen

Zeit	Aktuelle Nachrichten
13.12.	EMPEROR INT'L (00163): ANNOUNCEMENT PURSUANT TO RULES 13.51B(2) AND 13.51(2)(L) OF THE LISTING RULES
12.12.	EMPEROR INT'L (00163): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS
12.12.	EMPEROR INT'L (00163): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM
12.12.	EMPEROR INT'L (00163): 2024/2025 INTERIM REPORT
27.11.	EMPEROR INT'L (00163): 2024/2025 INTERIM RESULTS ANNOUNCEMENT

Zeit

Aktuelle Nachrichten

13.12.

EMPEROR INT'L (00163): ANNOUNCEMENT PURSUANT TO RULES 13.51B(2) AND 13.51(2)(L) OF THE LISTING RULES

12.12.

EMPEROR INT'L (00163): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS

12.12.

EMPEROR INT'L (00163): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM

12.12.

EMPEROR INT'L (00163): 2024/2025 INTERIM REPORT

27.11.

EMPEROR INT'L (00163): 2024/2025 INTERIM RESULTS ANNOUNCEMENT

Zeit	Aktuelle Nachrichten
Fr	IMMUNOVIA AB: Immunovia discovery study published in top protein research journal
19.12.	Immunovia AB: End of the Year 2024 Letter from Immunovia CEO Jeff Borcherding	LUND, Sweden, Dec. 19, 2024 /PRNewswire/ -- As we near the holidays and year end, I am energized by what Immunovia has accomplished in 2024 and the opportunities... ► Artikel lesen
18.12.	IMMUNOVIA AB: Immunovia CEO and board members announce intention to fully exercise their TO2 warrants
16.12.	IMMUNOVIA AB: Immunovia to host a webcast with the opportunity to learn more about the positive clinical validation of its next-generation pancreatic cancer test
11.12.	IMMUNOVIA AB: Immunovia announces financial calendar for financial year 2025/2026

Zeit

Aktuelle Nachrichten

IMMUNOVIA AB: Immunovia discovery study published in top protein research journal

19.12.

Immunovia AB: End of the Year 2024 Letter from Immunovia CEO Jeff Borcherding

LUND, Sweden, Dec. 19, 2024 /PRNewswire/ -- As we near the holidays and year end, I am energized by what Immunovia has accomplished in 2024 and the opportunities...
► Artikel lesen

18.12.

IMMUNOVIA AB: Immunovia CEO and board members announce intention to fully exercise their TO2 warrants

16.12.

IMMUNOVIA AB: Immunovia to host a webcast with the opportunity to learn more about the positive clinical validation of its next-generation pancreatic cancer test

11.12.

IMMUNOVIA AB: Immunovia announces financial calendar for financial year 2025/2026

Zeit	Aktuelle Nachrichten
Mo	Magnora ASA: Repurchase of shares
16.12.	Magnora ASA: Repurchase of shares
09.12.	Magnora ASA: Repurchase of shares
02.12.	Magnora ASA: Repurchase of shares
25.11.	Magnora ASA: Repurchase of shares

Zeit

Aktuelle Nachrichten